drugset / Trial / NCT02193360
Pilot Study of FFP104 Dose Escalation in PBC Subjects
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the initial safety, tolerability and pharmacodynamics of the CD40-antagonist Mab, FFP104, in subjects with PBC
Timeline
- Start
- 2015-05
- Primary completion
- 2017-08
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FFP104 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | FFP104 | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | FFP104 | Monoclonal antibody | 5 mg/kg | Intravenous |